Compositions and methods for diagnosis, treatment and prevention of kidney disease
By detecting and regulating the expression of xanthine oxidase and xanthine dehydrogenase, combined with uric acid-lowering agents and targeted treatment, the kidney damage caused by uric acid in polycystic kidney disease is solved, effective diagnosis and treatment is achieved, and the disease is delayed Progress and improvement of renal function.
Patent Information
- Application Number
- CN202280091990.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-04
- Filing Date
- 2022-12-20
- Publication Date
- 2024-11-22
AI Technical Summary
Increased serum concentration of uric acid in polycystic kidney disease leads to an increase in kidney size and reduced function, and existing diagnostic and therapeutic methods are difficult to effectively identify and regulate the mechanism of renal injury.
Decrease XO/XDH in the kidneys by detecting and regulating the expression of xanthine oxidase (XO) and xanthine dehydrogenase (XDH), using uric acid-lowering agents and targeted therapy, combined with inhibitory RNA (iRNA or siRNA), to reduce XO/XDH in the kidneys by detecting and regulating the expression of xanthine oxidase (XO) and xanthine dehydrogenase (XDH), using uric acid-lowering agents and targeted therapy methods, combined with inhibitory RNA (iRNA or siRNA), to reduce XO/XDH in the kidneys Expression, inhibit its overexpression to reduce renal damage.
Effectively diagnose and treat polycystic kidney disease, reduce renal damage, delay disease progression, reduce uric acid levels, and improve renal function.
Smart Images

Figure CN119013415A_ABST
Abstract
Description
Background Art
[0001] Polycystic kidney disease is characterized by a constellation of anatomical and physiological abnormalities such as hypertension, endothelial dysfunction, cardiovascular disease, liver disease, abnormalities involving large, medium and small caliber blood vessels and other health problems encountered by patients with polycystic kidney disease. There are two main causes of polycystic kidney disease, which are divided into two categories, namely, hereditary-autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). Other causes of polycystic kidney disease or cystic disease syndrome are found to be associated with cystic fibrosis, renal dysplasia, tuberous sclerosis, Hippel-Lindau syndrome, polycystic dysplasia of the kidney (MCDK), medullary sponge kidney and acquired renal cysts. Although the origin of polycystic kidney disease is usually genetic and is the main cause of the disease, the approach to diagnosing and treating the existing disease can be divided into primary prevention, secondary prevention and tertiary prevention. The progression of the disease is often variable, and some, but not all, identifiable conditions cause or allow polycystic kidney disease to develop, such as 1) pancreatic disease, 2) hormonal abnormalities, 3) drug or chemical induction, 4) tubular abnormalities, 5) genetic syndromes, and 6) others.
[0002] The two main causes of polycystic kidney disease are ADPKD and ARPKD, two genetic diseases that account for approximately 90% and 5% of all primary polycystic kidney disease, respectively. Symptoms frequently associated with polycystic kidney disease may or may not include hypertension, cardiovascular disease, endothelial dysfunction, hyperuricemia, gout, kidney stones, hematuria, abdominal pain, frequent urinary tract infections, headaches, abnormal heart valve structure, purpura, fatigue, and nausea and vomiting.
[0003] Many forms of kidney disease develop with an accelerated loss of filtering capacity. Summary of the invention
[0004] The embodiments described herein are based on the significant discovery that increased serum concentrations of uric acid in polycystic kidney disease are the primary mediators of increased kidney size and decreased renal function. In addition, the inventors' significant discovery is that increased expression and increased activity of xanthine oxidase / xanthine dehydrogenase in polycystic kidneys were found and can serve as mediators of renal injury. The following discovery is also described: polycystic kidneys uniquely express injury modulators, which are different from the effects of circulating serum uric acid, and targeted tissue expression of xanthine oxidase or modulators of xanthine oxidase expression represent new opportunities for this newly discovered injury mechanism. Aspects of the present invention provide a new method for diagnosing and treating the gradual decline in structural integrity and function of polycystic kidneys.
[0005] In a specific embodiment, the present subject matter relates to a method of detecting both increased tissue expression of xanthine oxidase (XO) and increased expression of xanthine dehydrogenase (XDH) in an individual susceptible to polycystic disease.
[0006] In a specific embodiment, the subject matter of the present invention relates to a method for detecting increased tissue expression of biosignal molecules (e.g., regulators of cytokine expression, inflammatory systems and / or proteome expression), which are regulated by increased XO / XDH expression in individuals prone to progression or accelerated progression of polycystic kidney disease.
[0007] In a specific embodiment, methods are provided for detecting, stratifying, identifying and treating individuals whose tissue XO / XDH increases their risk of polycystic kidney disease. As a treatment method, serum or urine samples can be obtained and tested, and serum uric acid or extracellular vesicles or cell membrane components can be tested to determine XO / XDH overexpression, and can be monitored in conjunction with the administration of uric acid-lowering agents.
[0008] In another embodiment, compositions and formulations of uric acid lowering agents that improve the absorption or bioavailability of uric acid lowering agents, and dosages, routes or delivery regimens thereof are provided. As a treatment method, serum or urine samples can be obtained and tested, so that serum uric acid or extracellular vesicles or cell membrane components can be tested to determine XO / XDH overexpression, and can be monitored in conjunction with the administration of uric acid lowering agents and / or agents that reduce XO / XDH expression.
[0009] In another embodiment, a method is provided for reducing the expression of xanthine oxidase or xanthine dehydrogenase in tissues, more specifically in the kidney, using inhibitory RNA (iRNA or siRNA). As a treatment method, serum or urine samples can be obtained and tested, so that serum uric acid or extracellular vesicles or cell membrane components can be tested to determine that XO / XDH is overexpressed, and can be monitored in conjunction with the administration of uric acid-lowering agents.
[0010] In another embodiment, a method is provided involving delivery of iRNA or siRNA to tissues where XO or XDH is overexpressed, to target the desired tissue or tissues for treatment. As a treatment method, serum or urine samples can be obtained and tested, so that serum uric acid or extracellular vesicles or cell membrane components can be tested to determine XO / XDH overexpression, and can be monitored in conjunction with the administration of uric acid-lowering agents.
[0011] In another embodiment, methods of reducing the risk of developing, delaying the onset of, and / or treating progressive kidney disease, more specifically polycystic kidney disease, are provided.
[0012] In another embodiment, methods of reducing the risk of developing, delaying the onset of, and / or treating progressive liver disease, more specifically polycystic liver disease, are provided.
[0013] In another embodiment, the present subject matter provides a method of specifically treating polycystic kidney disease to reduce damage associated with tissue-specific expression of xanthine oxidase or XO / XDH.
[0014] Another embodiment relates to a method of specifically treating cystic disease in a tissue to reduce damage associated with tissue-specific expression of XO, XDH, or XO / XDH expression, in combination with a xanthine oxidase inhibitor and an agent capable of reducing or modulating XO / XDH expression in a tissue.
[0015] Also provided are methods for specifically treating cystic disease in a tissue by increasing expression of upstream regulators, such as Sirtuin expression, more specifically Sirtuin-1 expression, as a means of regulating tissue-specific expression of XO / XDH.
[0016] Another embodiment relates to a composition comprising gliflozin and a xanthine oxidase inhibitor. It is believed that gliflozin increases the water solubility and oral bioavailability of the xanthine oxidase inhibitor. In addition, as described herein, gliflozin also has further functional benefits, making it particularly beneficial for cystic kidney disease when used in combination with other UALAs. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1: Purine metabolism and purine-based xanthine oxidase inhibitor metabolism Schematic diagram of .
[0018] Figure 2: Modulators of Xanthine Oxidase / Xanthine Dehydrogenase Schematic diagram of .
[0019] Figure 3: Schematic diagram showing that animal models of polycystic kidney disease display high serum allantoin concentrations.
[0020] Figure 4: Provides data demonstrating increased renal tissue expression of XO in rodent models of polycystic kidney disease. Figure 4A provides a Western blot showing increased expression of xanthine oxidase. Figure 4B provides data from kidneys of Han / SPDR (CY / +) rat models of polycystic kidney disease or wild-type rats. Light microscopy images of renal tissue sections stained for the presence of xanthine oxidase and read in relative density units (RD). Han / SDR showed an increased proportion of cytoplasmic staining compared to wild-type (p<0.05), and 4C provides evidence for similar observations in a mouse model of polycystic kidney disease (Pkd1 RC / RC mice) (p<0.05).
[0021] Figure 5: Increased XO activity in a rodent model of polycystic kidney disease kidney tissue compared to wild type.
[0022] Figure 6: Data presented show that in a rat model of polycystic kidney disease (PCK) and a mouse model of polycystic kidney disease (Pkd1RC / RC), uricase inhibition by oxonic acid (OXO) and the corresponding increase in uric acid are associated with an increase in the ratio of total kidney to body weight (2K / BWT). After 70 days of exposure to oxonic acid, both models showed similar results, with increases in serum uric acid leading to increased 2K / BWT, increased cyst size, and increased serum creatinine (P<0.05; P<0.05; P<0.07 and P<0.05 for creatinine in rats and mice). Increased serum uric acid is associated with structural and functional changes in renal function. Increased creatinine is associated with decreased filtration capacity in nephrotic kidney disease.
[0023] Figure 7: Presents data demonstrating that in a rodent model of polycystic kidney disease, uricase inhibition by oxonic acid and corresponding increases in uric acid indicate decreased renal function as shown by increased creatinine in serum.
[0024] Figure 8 : In a rodent model of polycystic kidney disease—the mouse RC / RC model—xanthine oxidase inhibition slowed the progression of renal disease, as measured by mean total kidney volume ( Figure 8 A) and the median size of the kidney ( Figure 8 B) indicated.
[0025] Fig. 9 : In a rodent model of polycystic kidney disease, mice RC / RC, oxonic acid (OXO) exposure increased kidney size. When OXO and xanthine oxidase inhibition ("OXY+L", oxypurinol and L-arginine) were co-administered, OXY+L attenuated OXO effects at moderate (8 mg / kg / day) or higher oral doses (24 mg / kg / day) and normalized / reduced uric acid-induced kidney dilatation.
[0026] FIG. 10 shows an embodiment of a diagnostic device. DETAILED DESCRIPTION
[0027] The present invention relates to methods of diagnosis, methods of treatment and uses of agents that affect abnormal purine metabolism. The present invention relates to methods of diagnosing abnormal purine metabolism in tissues, methods of controlling abnormal purine metabolism in tissues and methods of treating abnormal adenine metabolism in tissues.
[0028] The present invention relates to the use of xanthine oxidase inhibitors in polycystic kidney disease and / or a combination of agents capable of reducing tissue expression of xanthine oxidase or xanthine oxidase activity.
[0029] The data presented herein suggest that when tissue expression of XO / XOR contributes to intracellular uric acid and oxygen free radical production, this may contribute to mitochondrial damage, vascular or structural damage, inflammation or fibrosis, without being limited by this theory. Compositions and methods are provided to ameliorate such deleterious effects.
[0030] Also provided are treatments of ADPKD by the therapeutic use of xanthine oxidase inhibitors or free oxygen radical scavengers, or molecules having both properties, to specifically inhibit intracellular, renal or other tissue damage.
[0031] In addition, XOIs combined with anti-inflammatory or antifibrotic drugs could be used to protect the kidneys from disease progression.
[0032] Furthermore, XOIs in combination with “vasopressin receptor antagonists” such as tolvaptan, rivaptan or other “-vaptans” trigger cyst / cyst growth or increase in total kidney volume, slow functional decline, and reduce the health consequences of extracellular and intracellular xanthine oxidase.
[0033] In addition, an effector of xanthine oxidase / xanthine dehydrogenase (XO / XDH) expression or activity or an effector of the XO / XDH ratio, such as an SGLT2 inhibitor or a Sirtuin 1 activator that is capable of directly or indirectly regulating XO / XDH, is administered to a subject having symptoms of PKD.
[0034] Additionally, silencing of genes, such as xanthine oxidase (XO), thioredoxin interacting protein (TXNIP), and / or nuclear factor erythroid 2-related factor (nrf-2 / heme oxygenase 1 (HO-1)), using interfering molecules directed against the expression of these genes to reverse the health consequences of overexpression is disclosed.
[0035] According to certain embodiments, a method for detecting and treating the progression of renal disease in a subject is provided. The method comprises obtaining a sample from the subject; and detecting the expression or activity level of xanthine oxidase in the sample, and determining that the subject is a subject in need if the expression or activity level of xanthine oxidase is at or above a predetermined level or is elevated relative to a control; and administering a therapeutically effective amount of a xanthine oxidase inhibitor to the subject in need.
[0036] A method is also provided, comprising detecting changes in xanthine oxidase (XO) concentration or activity or xanthine dehydrogenase (XDH) concentration or activity or XO / XDH concentration or activity ratio. The method comprises obtaining a sample from a subject having one or more symptoms of polycystic kidney disease, wherein the sample comprises a blood sample or a urine sample, or an extracellular vesicle sample from a blood sample or a urine sample; detecting the XO concentration or activity and the XDH concentration or activity in the sample; and administering UALA and optionally co-administering an organic base if the XO concentration or activity, XDH concentration or activity and / or XO / XDH concentration or activity ratio contained in the sample deviates from that of a healthy subject. In a specific example, the deviation from a healthy subject is an XO concentration greater than 1 mg / L; an XO enzyme activity greater than 105 (U / L); and / or an XO / XDH difference of at least 0.1-10% from that of a healthy subject.
[0037] Another method embodiment relates to a method for reducing abnormal purine metabolism associated with kidney disease in a subject in need thereof. This embodiment relates to administering a therapeutically effective amount of one or more uric acid lowering agents, wherein the method treats the symptoms of cystic disease, and wherein the one or more uric acid lowering agents are optionally selected from the group consisting of xanthine oxidase inhibitors and sirtuin-1 activators. In a specific embodiment, administration comprises the combined administration of oxypurinol and gliflozin.
[0038] In yet another embodiment, a method for reducing a subject's renal disease progression marker is provided. The method comprises obtaining a sample from a subject; detecting a marker of renal disease, the marker comprising tissue oxygen free radicals, uric acid, cytokines, inflammatory cells, fibrosis, mitochondrial hyperplasia or Sirtuin-1 in the sample, and if the level of the marker is higher than the baseline, administering a therapeutically effective amount of UALA to a subject in need, and optionally administering an organic base in combination. In a specific example, UALA is an interfering molecule targeting the expression of xanthine oxidase or xanthine dehydrogenase, or an eRNA that increases the expression of sirtuin-1. In a more specific embodiment, administration comprises the combined administration of a xanthine oxidase inhibitor and an interfering molecule targeting the expression of xanthine oxidase or xanthine dehydrogenase.
[0039] A method is also provided, comprising detecting the presence of a marker or a ratio of a marker in a biological sample from a subject; if the marker is elevated relative to a baseline or a control, or if the ratio of the marker is disproportionate to the baseline or the control, administering to the subject a therapeutically effective amount of at least one uric acid-lowering agent. The marker may be one or more of xanthine oxidase, xanthine dehydrogenase, sirtuin or sirtuin-1, hypoxia-inducible factor-1 (HIF-1), erythropoietin, PCNA, Wnt / B-catenin, IL-5, IL-6, STAT1, STAT2, mTOR, TNFa, MIF, NLRP3 inflammasome, or a component of a cell membrane, microvesicle, apoptotic body, exosome carried by blood or urine, or a free enzyme or a specific part / fragment of an enzyme.
[0040] Other method embodiments relate to methods for monitoring the effectiveness of polycystic kidney disease treatment. The method comprises administering a dose of a uric acid-lowering agent to a subject whose xanthine oxidase activity or concentration in urine is increased or whose xanthine oxidase / xanthine dehydrogenase activity or concentration ratio is increased relative to baseline; and detecting the xanthine oxidase concentration or activity or xanthine oxidase / xanthine dehydrogenase concentration or activity ratio in the subject's urine, wherein a decrease in xanthine oxidase activity or concentration or a shift in xanthine oxidase / xanthine dehydrogenase concentration or activity ratio toward baseline indicates that the treatment is effective. Another method embodiment relates to a method for treating polycystic kidney disease, comprising administering a therapeutically effective amount of a xanthine oxide inhibitor and metformin in combination.
[0041] Also disclosed is a composition comprising an amount of oxypurinol and an amount of metformin and / or an SGLT2 inhibitor. In a specific embodiment, the composition comprises oxypurinol, metformin and gliflozin.
[0042] In an alternative method embodiment, a method of treating polycystic kidney disease is provided comprising administering a therapeutically effective amount of a xanthine oxide inhibitor in combination with tolvaptan and / or rivaptan.
[0043] In a related embodiment, a composition is provided, comprising a therapeutically effective amount of a uric acid lowering agent and a therapeutically effective amount of tolvaptan and / or rivaptan. In a specific example, UALA is a xanthine oxidase inhibitor.
[0044] Also disclosed is a method of treating a cystic disease in a subject in need thereof, the method comprising co-administering a therapeutically effective amount of a uric acid lowering agent and a gliflozin, wherein the gliflozin is co-administered in an amount that increases the aqueous solubility and bioavailability of the uric acid lowering agent.
[0045] In another embodiment, a method for treating cystic disease is provided, comprising administering a therapeutically effective amount of a xanthine oxidase inhibitor and a Sirtuin-1 activator in combination. In a specific example, the Sirtuin-1 activator is an SGLT2 inhibitor.
[0046] In another embodiment, a method for treating a cystic disease in a subject in need thereof is provided, comprising administering in combination a therapeutically effective amount of at least one xanthine oxidase inhibitor and an agent that directly or indirectly reduces the expression of xanthine oxidase. The agent that directly reduces the expression of xanthine oxidase may include an interfering molecule that targets the expression of xanthine oxidase. The agent that indirectly reduces the expression of xanthine oxidase may include a sirtuin-1 activator. In a specific example, the sirtuin-1 activator includes gliflozin or an eRNA that induces sirtuin-1 expression, or a combination thereof.
[0047] In a related embodiment, a composition is provided comprising a therapeutically effective amount of a xanthine oxidase inhibitor and an agent that directly or indirectly reduces the expression of xanthine oxidase. The agent that directly reduces the expression of xanthine oxidase may include an interfering molecule that targets the expression of xanthine oxidase. The agent that indirectly reduces the expression of xanthine oxidase may include a sirtuin-1 activator. In a specific embodiment, the sirtuin-1 activator includes gliflozin or an eRNA that induces the expression of sirtuin-1, or a combination thereof. definition
[0048] Preferred materials and methods are described herein; any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. Unless otherwise specified, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. The following terms will be used in describing and claiming the present invention. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.
[0049] When a numerical range is given, it is understood that each intermediate value between the upper and lower limits of the range (to one tenth of the lower limit unit, unless the context clearly indicates otherwise) and any other stated value or intermediate value in the stated range are included in the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller range and are also included in the present invention, subject to any clear exclusion limit in the stated range. If the stated range includes one or two limits, the range excluding any one or two of these included limits is also included in the present invention.
[0050] Unless otherwise specifically stated, as used herein, "a", "an", "the", etc. refer to one or more (i.e., at least one) of its grammatical objects. For example, "an element" refers to one or more elements. Unless otherwise stated, "or" includes "and". For illustration, "A, B, or C" refers to A alone, B alone, C alone, the combination of A and B, the combination of A and C, the combination of B and C, and the combination of A, B, and C, unless otherwise stated.
[0051] The use of any and all examples or exemplary language (e.g., "such as") provided with respect to certain embodiments herein is intended only to better illustrate the present invention and is not intended to limit the scope of the invention as claimed. No language in the specification should be construed as indicating that any non-claimed element is essential to the practice of the present invention.
[0052] Unless otherwise expressly stated, all features disclosed in this specification (including any attached claims, abstracts and drawings) may be replaced by alternative features used for the same, equivalent or similar purposes. Therefore, unless otherwise expressly stated, each feature disclosed is merely an example of a general series of equivalent or similar features. The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes may be made thereto by those of ordinary skill in the art, which are included in the spirit and scope of the present application. Many changes and modifications may be made to the embodiments of the present invention without substantially departing from the spirit and principles of the present invention. All these modifications and changes are included within the scope of the present invention. For example, unless otherwise stated, the present invention is not limited to specific materials, reagents, reaction materials, manufacturing processes, etc., because these may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting. In the present invention, the steps may also be performed in different orders where logically possible.
[0053] The term "abnormal purine metabolism" as used herein refers to a level of metabolites of purine conversion such as xanthine, uric acid (or urate) and / or allantoin that is higher than that of healthy subjects. Abnormal purine metabolism is generally associated with elevated expression and / or activity of xanthine oxidase in cells of subjects showing symptoms of one or more diseases (e.g., polycystic kidney disease, cystic liver disease or cystic disease or any disease in which the expression or activity of xanthine oxidase in tissues is increased).
[0054] The word "administer" or its other grammatical forms refers to any route of introducing or delivering a compound or agent to a subject to exert its intended function. Administration can be performed by any suitable route, including oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal or topical administration. Administration includes self-administration and administration by another person.
[0055] The term "antisense sequence" as used herein refers to an oligomeric compound that is at least partially complementary to a target nucleic acid molecule that hybridizes therewith. In certain embodiments, the antisense compound regulates (increases or decreases) the expression of the target nucleic acid. Antisense compounds include, but are not limited to, compounds that are oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimics, and chimeric combinations thereof.
[0056] As used herein, the term "co-administered" or "simultaneous administration", when used, for example, with respect to the administration of an exemplary therapeutic agent with another exemplary therapeutic agent or a combination agent with an exemplary therapeutic agent, refers to the administration of an exemplary therapeutic agent and another exemplary therapeutic agent or combination agent so that both can achieve a physiological effect simultaneously. However, the two agents do not need to be administered together. In some embodiments, the administration of one agent may precede the administration of the other agent, however, such co-administration generally results in the simultaneous presence of the two agents in the subject's body (e.g., in the plasma).
[0057] As used herein, "composition", "pharmaceutical composition" or "therapeutic agent" all include compositions comprising at least a uric acid lowering agent. Optionally, the "composition", "pharmaceutical composition" or "therapeutic agent" further includes a pharmaceutically acceptable diluent or carrier and / or a co-agent. In the case of an interfering molecule, for example, the interfering molecule can be combined with one or more pharmaceutically acceptable diluents, such as phosphate buffered saline.
[0058] The term "control" when used in describing a comparison to a marker or a marker ratio refers to the level of a molecule or a ratio representative of a molecule present in a sample from a healthy subject.
[0059] The term "cystic disease" as used herein refers to any disease of a tissue that includes increased cystogenesis or cyst growth relative to healthy individuals. Cystic diseases describe a group of diseases that lead to the formation of cysts (fluid-filled sacs) in or around organs. Cyst growth or expansion may be associated with increased pressure on healthy tissue surrounding the cyst, resulting in reduced blood circulation, nutrient exchange, or metabolites that regulate disease progression. The expression of xanthine oxidase / xanthine dehydrogenase (XO / XDH) or the ratio of XO / XDH in cystic tissue can lead to direct accumulation of uric acid in the tissue, or accumulation of oxygen free radicals in the tissue, directly or indirectly promoting disease or disease progression in the tissue.
[0060] The term "cystic kidney disease" causes cysts (fluid sacs) to form in or around the kidneys. There are different types of cystic kidney disease. Some are the result of abnormal genes; others develop in the womb or are the result of kidney failure. Both adults and infants can develop cystic kidney disease. The term cystic kidney disease includes polycystic kidney disease.
[0061] Enhancer RNA or eRNA used herein refers to a short non-coding RNA molecule transcribed from the locus of the enhancer. The application of eRNA associated with the enhancer of the target gene can increase the expression of the target gene. The enhancer is a regulatory element in the genome that cooperates with the promoter to control the transcription of the target gene and the fate of the cells next to the promoter. Gene promoters such as uricase or sirtuin may be particularly useful for regulating disease progression. The sequence of human sirtuin 1 is shown in accession numbers NM_012238, NM_001142498 and NM_001314049.
[0062] As used herein, "extracellular vesicles" include "exosomes" or "microvesicles (MVs)", which, in some embodiments, are released by almost all types of cells when their multivesicular bodies fuse with the plasma membrane of the cell. The term "extracellular vesicle" may include both exosomes and MVs. Extracellular vesicles are present in many (if not all) eukaryotic fluids, including blood, urine, and culture medium for cell culture. Extracellular vesicles, particularly exosomes or MVs, are well known for their role in intercellular communication, and have been shown to have the ability to unload their contents and help transform normal cells and stem cells into cancerous states. For example, microvesicles can be formed by a variety of processes, including the release of apoptotic bodies, microvesicles budding directly from the plasma membrane of cells, and exocytosis of multivesicular bodies. For example, extracellular vesicles are usually formed by secretion from the endosomal membrane compartment of the cell due to the fusion of multivesicular bodies with the plasma membrane. Multivesicular bodies (MVBs) are formed by budding inward from the endosomal membrane and then pinching off small vesicles into the luminal space. The internal vesicles present in MVBs are then released into the extracellular fluid as so-called exosomes or extracellular vesicles.
[0063] The term "healthy subject" refers to a subject who does not have symptoms of a disease or a genetic predisposition to a disease. In a specific example, a healthy subject does not show symptoms of polycystic kidney disease, and / or does not have a genetic predisposition to PKD.
[0064] The term "inhibitory oligonucleotide" refers to any oligonucleotide that, for example, reduces protein production or expression by interfering with the translation of mRNA into protein in ribosomes, or is sufficiently complementary to, specifically binds (hybridizes) one or more targeted genes or mRNAs encoding one or more targeted proteins, thereby reducing the expression or biological activity of the targeted protein. Inhibitory oligonucleotides include isolated or synthetic shRNA or DNA, siRNA or DNA, antisense RNA or DNA, chimeric antisense DNA or RNA, miRNA and miRNA mimics, etc.
[0065] The term "interfering molecule" as used herein refers to all molecules that have a direct or indirect effect (e.g., silencing target gene sequence) on gene expression. Interfering molecules include inhibitory oligonucleotides, RNA interfering molecules, and RNA-like interfering molecules. Examples of interfering RNA molecules include antisense sequences, siRNA, short hairpin RNA (shRNA), single-stranded siRNA, microRNA (miRNA), methylated siRNA, or other siRNAs and dicer-substrate 27-mer duplexes that are treated to protect siRNA from degradation by cyclic RNA enzymes. Examples of "RNA-like" molecules include, but are not limited to, siRNA, single-stranded siRNA, microRNA, and shRNA molecules, which contain one or more chemically modified nucleotides, one or more non-nucleotides, one or more deoxyribonucleotides, and one or more non-phosphodiester bonds. Therefore, siRNA, single-stranded siRNA, shRNA, miRNA, and dicer-substrate 27-mer duplexes are all subsets of "interfering molecules." "Interfering molecules" may also include PMOs. See U.S. Patent Publication No. 20200299698, Chinese Patent CN104232644; or Wang et al. Oxid Med Cell Longev, 2022, 2022: 4326695, and Origene Technologies (Cat No. TF308350).
[0066] The term "marker" or "biomarker" as used herein refers to a biological molecule whose presence or relative presence compared to a baseline or control indicates a disease or condition. In the present invention, examples of markers include xanthine oxidase and / or xanthine dehydrogenase (or nucleic acid sequences encoding them or fragments thereof), antigens associated with xanthine oxidase and / or xanthine dehydrogenase, and / or genetic markers of uric acid and / or PKD.
[0067] The term "metformin" refers to metformin or a pharmaceutically acceptable salt thereof. See U.S. Patent Nos. 6,031,004, RE46496 and 10,154,972.
[0068] The term microRNA (abbreviated as miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals and some viruses, whose function is RNA silencing and post-transcriptional regulation of gene expression. miRNA is similar to the small interfering RNA (siRNA) of the RNA interference (RNAi) pathway, but miRNA is derived from the region of the RNA transcript itself that folds to form a short hairpin, while siRNA is derived from a longer region of double-stranded RNA. Experimentally confirmed miRNAs are assigned names according to a standard naming system. The prefix "miR" is followed by a dash and a number, the latter of which usually indicates the order of naming. "MIR" refers to the gene encoding the corresponding miRNA. Different miRNAs with almost identical sequences except for one or two nucleotides are annotated with additional lowercase letters. The term miRNA mimics refers to small double-stranded RNA molecules, such as siRNA, that are designed to mimic endogenous mature miRNA molecules when introduced into cells.
[0069] The term "organic base" as used herein refers to a class 1 base with (a) pKa1 of about 7 to 13, including but not limited to L-arginine, D-arginine, choline, L-lysine, D-lysine and caffeine. In an alternative embodiment, the organic base is a biguanide (U.S. Patent No. 9,480,663) or a biguanide, such as metformin, phenformin, buformin or their salts. It is worth noting that metformin has a variety of beneficial effects in the compositions and methods described herein. First, it can be used as a solubilizer for oxypurinol to improve oral bioavailability. Secondly, it can be used as an alkalizing agent. Again, metformin can be used as a uric acid solubilizer here. An unexpected effect of metformin is that the ratio of oxypurinol to metformin 1:01 to 1:10 increases the solubility of oxypurinol from 0.2 mg / ml to 16.8 mg / ml or higher. The gliflozin family of SGLT2 inhibitors is also alkaline and can be used as an organic base according to the teachings of this article.
[0070] The term "phosphorothioate morpholino oligomer" or "PMO" as used herein refers to a molecule whose nucleic acid base is identical to the naturally occurring nucleic acid base in RNA or DNA (i.e., adenine, cytosine, guanine, uracil, or thymine) but is bound to a morpholine ring rather than the ribose ring used by RNA. They can also be linked via a phosphorodiamidate rather than a phosphodiester or phosphorothioate group. This linkage modification eliminates ionization within the normal physiological pH range, so the PMO in an organism or cell is an uncharged molecule. The entire backbone of the PMO is composed of these modified subunits.
[0071] As used herein, the term "polycystic kidney disease" or "PKD" refers to a genetic disease in which abnormalities in the structure of the renal tubules lead to the development and growth of multiple cysts within the kidneys. These cysts may begin to develop in utero, in infancy, childhood, or adulthood. A cyst is a non-functioning tubule that is filled with accumulated fluid and can range in size from tiny to large, squeezing or compressing adjacent normal tubules and / or healthy adjacent tissues and blood vessels, ultimately rendering them incapable of functioning.
[0072] The term "prevention" as used herein refers to preventing the clinical symptoms of a disease from developing in a subject who may be exposed to or susceptible to a disease but has not yet experienced or shown symptoms of the disease, such as inhibiting the onset of the disease. The term used herein may further include 1) reducing the frequency or severity of symptoms typically associated with the disease; or 2) delaying or avoiding other symptoms associated with a condition or disease, or preventing the disease altogether. Those skilled in the art will recognize that various embodiments relate to preventive methods, and subjects in need (i.e., subjects in need of prevention) should include any subject or patient (preferably a mammal, more preferably a human) who has experienced or shown at least one symptom of a condition, disease or condition to be prevented. In addition, subjects in need may also be subjects (preferably mammals, more preferably humans) who do not show any symptoms of a condition, disease or condition to be prevented, but who are considered by doctors, clinicians or other medical professionals to be at risk of developing the condition, disease or condition. For example, due to the subject's medical history, including but not limited to family history, susceptibility to disease, coexisting (comorbid) conditions or conditions, genetic testing, etc., the subject may be considered to be at risk of developing a condition, disease or condition (therefore prevention or preventive treatment is required).
[0073] The term SGLT2 inhibitor used herein refers to a sodium-glucose co-transporter inhibitor. The non-limiting list of SGLT2 inhibitors includes, but is not limited to, "gliflozin", such as empagliflozin, dapagliflozin, canagliflozin, ergliflozin, ipagliflozin, rugliflozin, regliagliflozin, sergliflozin, sotagliflozin or togliflozin. It has been found that gliflozin has multifunctional properties and is particularly beneficial for treating cystic kidney disease. Gliflozin can activate the function of sirtuin-1 and reduce the expression of xanthine oxidase, increase the bioavailability of other uric acid lowering agents such as xanthine oxidase inhibitors with its alkaline function, and itself can inhibit xanthine oxidase activity. Therefore, gliflozin belongs to the definition scope of uric acid lowering agents, xanthine oxidase inhibitors, sirtuin-1 activators and organic bases. Unless otherwise stated, when it is stated or claimed that gliflozin is combined or co-administered with one or more of these four types of agents, this is to convey that in this context, gliflozin can perform an additional function relative to the function of the agent with which it is combined or co-administered. For example, a composition comprising UALA and gliflozin means that gliflozin can be used as an agent other than UALA and UALA, such as an organic base, to increase the bioavailability of UALA.
[0074] As used herein, "shRNA" (small hairpin RNA) is a short "hairpin" RNA sequence that can be used to inhibit or prevent gene expression.
[0075] As used herein, "siRNA" (short interfering RNA), also known as small interfering RNA or silencing RNA, refers to a double-stranded RNA molecule, usually about 15-30 nucleotides in length, which is complementary to the sequence of mRNA molecules transcribed from a target gene and interferes with the expression of the target gene.
[0076] The term "sirtuin-1 activator" as used herein refers to an agent that can activate the sirtuin family of NAD+-dependent protein cleavage deacetylases and regulate various functions of sirtuin such as physiology, metabolism and stress response. More specifically, an agent that activates sirtuin-1 (SIRT-1) and thereby regulates the expression of xanthine oxidase, xanthine dehydrogenase in tissues or regulates the ratio of XO / XDH. Examples of agents that can activate sirtuin include resveratrol, epicatechin, quercetin, SRT2104, SRT1720, 1,4-DHP derivatives, UBCS039, SRT2104, SRT2379, SRT3025 or SGLT-2 inhibitors include "gliflozin", such as empagliflozin, dapagliflozin, canagliflozin and eRNA that induces sirtuin-1 expression. Other examples of sirtuin-1 activators are described in U.S. Patent Publication 20070149466.
[0077] As used herein, the term "subject" or "patient" refers to any animal (eg, mammal) to be treated with a particular treatment, including but not limited to humans, non-human primates, rodents, and the like.
[0078] As used herein, a "subject in need thereof" is a subject who exhibits one or more symptoms of PKD and / or is genetically predisposed to develop PKD. Symptoms of PKD may include increased kidney size, decreased renal function, increased cyst formation rate, increased cyst growth rate, increased hypertension, increased abdominal pain or back pain, increased cardiovascular disease, increased kidney stone formation rate, increased incidence of gout, increased incidence of renal failure, increased endothelial dysfunction, increased inflammatory states, increased rheumatoid arthritis, increased urinary tract infections, increased incidence of heart attacks or strokes, increased dialysis requirements, increased circulating creatinine concentrations, or serum uric acid concentrations greater than 6 mg / dL.
[0079] "Therapeutically effective amount" refers to an amount that, when administered in an appropriate administration regimen, is sufficient to reduce or improve the severity, duration or progression of the disease being treated (e.g., cancer), prevent the progression of the disease being treated (e.g., cancer), cause the disease being treated (e.g., cancer) to regress, or enhance or improve the preventive or therapeutic effect of another treatment. The complete therapeutic effect does not necessarily occur by administering one dose, but may only occur after administering a series of doses. Therefore, a therapeutically effective amount can be administered once or more per day for several consecutive days.
[0080] As used herein, the terms "treat" or "alleviate" refer to therapeutic treatment, wherein the goal is to stop, slow down or reverse a pathological condition or disorder. In one example, the terms may further include the administration of a compound to control the symptoms or underlying causes of a disease, with the goal of reducing the symptoms or signs of the disease, to prevent or slow progression, to arrest or potentially reverse the manifestations of the disease or to inhibit the underlying mechanisms causing the disease.
[0081] The term "uric acid lowering agent" or UALA refers to a substance known to reduce serum uric acid levels in mammals. Typically, UALA can limit serum uric acid levels to at least about 0.2 mg / dl. UALAs include, but are not limited to, xanthine oxidase inhibitors; uricosurics such as beniodarone, benzbromarone, probenecid; uricase derivatives such as rasburicase and pegylated uricase; gene-based therapies such as uricase overexpression or URAT-1 blockade; supplements of uricase protein, which can be delivered with polyethylene glycol or a conjugate of another delivery system; interfering molecules targeting xanthine oxidase or xanthine dehydrogenase, sirtuin-1 activators such as SGLT-2 inhibitors (such as gliflozin), flavonoids such as resveratrol or eRNA that upregulates sirtuin-1 expression; and urate channel inhibitors. As described above, gliflozin has multiple mechanistic functions.
[0082] The term "xanthine oxidase inhibitor" as used herein refers to an agent that reduces the activity or expression of xanthine oxidase. Examples of xanthine oxidase inhibitors include, but are not limited to, allopurinol, oxypurinol, hydroxyakalone, TEI-6720, carprofen, febuxostat, topiroxostat, TMX-049, and y-700; inhibitory oligonucleotides or other interfering molecules targeting xanthine oxidase expression; or anti-xanthine oxidase antibodies. Xanthine oxidase inhibitors can be further defined by their ability to inhibit xanthine oxidase or xanthine dehydrogenase in blood, tissues, or fluids, or all, either alone or simultaneously, or by their prodrug metabolites.
[0083] The compound is preferably formulated into a suitable pharmaceutical preparation, such as a solution, suspension, tablet, dispersible tablet, pill, capsule, powder, sustained-release preparation or elixir for oral administration, or a sterile solution or suspension for parenteral administration, as well as a transdermal patch and a dry powder inhaler. Typically, the above-mentioned compound is formulated into a pharmaceutical composition using techniques and procedures well known in the art (see, for example, Ansel Introduction to Pharmaceutical Dosage Forms, 4th edition 1985, 126).
[0084] In the composition, one or more compounds or pharmaceutically acceptable derivatives at effective concentrations are mixed with a suitable pharmaceutical carrier or solvent. As described above, the compound can be derived into a corresponding salt, ester, enol ether or ester, acid, base, solvate, hydrate or prodrug before formulation. The concentration of the compound in the composition is effective for delivering an amount of at least 0.5 mg / dl to equal to or less than 5.5 mg / dl when administered. In the most preferred embodiment, the effective amount, for example, reduces serum uric acid levels to less than or equal to 5.5 mg / dl and greater than or equal to 4.0 mg / dl. Preferably, the effective amount, for example, reduces serum uric acid levels to less than or equal to 5.2 mg / dl and greater than or equal to 4.5 mg / dl.
[0085] UALA can be used simultaneously or sequentially (i.e., co-administered) with one or more known antioxidants, such as but not limited to vitamin C, alpha-lipoic acid, vitamin E, beta-carotene, selenium, zinc, carnosine, green tea, soybeans and isoflavones, tempol, etc. In other embodiments, a uric acid lowering agent is combined with a vasopressin receptor antagonist or SGLT-2 inhibitor or an agent capable of increasing the water solubility or bioavailability of a xanthine oxidase inhibitor. Regardless of the uric acid level, this combination may be beneficial, but if a UALA dose that reduces uric acid to less than 5.5 mg / dl is administered, it may be particularly helpful. In other embodiments, a uric acid lowering agent is co-administered with metformin. Therefore, in another embodiment, a composition comprising both a uric acid lowering agent and metformin is provided.
[0086] Typically, the composition is formulated for single-dose administration. In order to prepare the composition, a certain weight fraction of the compound is dissolved, suspended, dispersed or otherwise mixed in a selected solvent at an effective concentration, thereby alleviating or improving the disease being treated. Pharmaceutical carriers or vehicles suitable for administering the compounds provided herein include any such carriers known to those skilled in the art to be suitable for a particular mode of administration. In vitro diagnostic devices
[0087] FIG10 schematically illustrates an in vitro diagnostic device of the present invention, generally indicated at 10. The in vitro diagnostic device of the present invention comprises at least a sample collection chamber 13, an assay module 12 for detecting disease biomarkers, and a user interface associated with the biomarker concentration (level) tested in the assay module. The in vitro diagnostic device may be a handheld device, a desktop device, or a point-of-care device.
[0088] Sample chamber 13 can be any sample collection device known in the art for holding biological fluids. In one embodiment, the sample collection chamber can contain any biological fluid contemplated herein, such as whole blood, cells, cell suspensions, cell or tissue lysates, plasma, serum, urine, sweat or saliva.
[0089] The assay module 12 is preferably composed of an assay that can be used to detect proteins in biological samples, such as by using antibodies in an immunoassay. The assay module 12 can include any assay currently known in the art; however, the assay should be optimized for detecting markers for diagnosing a subject's disease (e.g., polycystic kidney disease), injury severity, or treatment response. The assay module 12 is in fluid communication with the sample collection chamber 13. In one embodiment, the assay module 12 is configured to perform an immunoassay, wherein the immunoassay can be any of a radioimmunoassay, an ELISA (enzyme-linked immunosorbent assay), a "sandwich" immunoassay, an immunoprecipitation assay, a precipitin reaction, a gel diffusion precipitin reaction, an immunodiffusion assay, a fluorescent immunoassay, a chemiluminescent immunoassay, a phosphorescent immunoassay, or an anodic stripping voltammetry immunoassay. Alternatively, the assay module is configured to perform a nucleic acid hybridization assay. In one embodiment, a colorimetric assay can be used, which can include only a sample collection chamber 13 and an assay module 12 for determination. Although not specifically shown, these components are preferably contained in a component 17.
[0090] In one embodiment, the in vitro diagnostic device of the present invention comprises a power supply 11, a determination module 12, a sample chamber 13 and a data processing module 14. The power supply 11 is electrically connected to the determination module and the data processing module 14. The determination module 12 and the data processing module 14 are in electrical communication with each other. As described above, the determination module 12 can include any determination currently known in the art; however, the determination should be optimized for detecting biomarkers for detecting damage, disease or repair of a subject herein. The determination module 12 is in fluid communication with the sample collection chamber 13. The determination module 12 includes an immunoassay, wherein the immunoassay can be any one of a radioimmunoassay, an ELISA (enzyme-linked immunosorbent assay), a "sandwich" immunoassay, an immunoprecipitation assay, a precipitin reaction, a gel diffusion precipitin reaction, an immunodiffusion assay, a fluorescent immunoassay, a chemiluminescent immunoassay, a phosphorescent immunoassay or an anodic stripping voltammetry immunoassay. The biological sample is placed in the sample chamber 13 and is determined by the determination module 12 for detecting the marker. The measured amount of the marker determined by the determination module 12 is then electrically transmitted to the data processing module 14. The data processing module 14 may include any known data processing elements familiar in the art, and may include a chip, a central processing unit (CPU), or a software package that processes the information provided by the determination module 12 .
[0091] In one embodiment, the data processing module 14 is in electronic communication with a display 15, a storage device 16, or an external device 18 or a software package [eg, laboratory and information management software (LIMS)].
[0092] In one embodiment, data processing module 14 is used to process data into a user-defined usable format. The format includes the measured concentration (level) of one or more markers detected in the sample for diagnosing a subject's disease (such as polycystic kidney disease), injury severity or treatment response. Information from data processing module 14 can be shown on display 15, saved in a storage device in a machine-readable format, or electrically communicated to external device 18 for additional processing or display. Although not specifically shown, these components are preferably contained in a component 17. In one embodiment, data processing module 14 can be programmed to compare the detected amount of the biomarker transmitted from determination module 12 with a comparator algorithm. The comparator algorithm can compare the measured amount with a user-defined threshold value, which can be any limit value available to the user. In one embodiment, the user-defined threshold value is set to the amount of the biomarker measured in the control subject, or the statistically significant mean value of the control population.
[0093] In one embodiment, the in vitro diagnostic device may include one or more devices, tools and equipment configured to hold or collect biological samples from individuals. In one embodiment of the in vitro diagnostic device, the tools for collecting biological samples may include one or more of needles, swabs, scalpels, syringes, scrapers, containers and other devices and reagents designed to facilitate the collection, storage and transportation of biological samples. In one embodiment, the in vitro diagnostic test may include reagents or solutions for collecting, stabilizing, storing and processing biological samples. These reagents include antibodies, aptamers or combinations thereof produced for one of the above-mentioned biomarkers. In one embodiment, the in vitro diagnostic device disclosed herein may include microarray devices and reagents, as well as other hardware and software necessary for measuring samples to detect and visualize time-related biomarkers. Reagent test kit
[0094] In another aspect, a kit for aiding in the diagnosis of injury, disease or repair (including type, stage, magnitude (severity), subcellular localization) is disclosed, wherein the kit is used to detect markers. For example, the kit can be used to detect any one or more biomarkers described herein, which are different in samples from patients and normal subjects. In another example, the kit can be used to identify compounds that modulate the expression of one or more markers in an in vitro or in vivo animal model to determine the effect of treatment.
[0095] In one embodiment, the kit includes (a) an antibody, aptamer or nucleic acid probe that specifically binds to the above-mentioned marker; and (b) a detection reagent. This kit is prepared from the above-mentioned materials, and the above discussion about materials (such as antibodies, aptamers, detection reagents, immobilized carriers, etc.) is fully applicable to this section, so it is not repeated. In one embodiment of the present invention, the kit includes (a) a composition of a detection agent for detecting one or more markers.
[0096] In one embodiment, the present invention includes a diagnostic kit for screening biological samples for the presence or different amounts of xanthine oxidase and / or xanthine dehydrogenase and / or uric acid and / or sirtuin-1. The diagnostic kit in this embodiment includes a substantially separated antibody or aptamer that specifically immunoreacts with a peptide or polynucleotide antigen, or a nucleic acid probe that hybridizes with a polynucleotide biomarker, and a visually detectable marker associated with the binding of a polynucleotide or peptide antigen to an antibody or aptamer or nucleic acid probe. In one embodiment, the antibody or aptamer is connected to a solid support. The antibodies or aptamers used in the kit of the present invention are those produced for any one of the biomarkers used herein for time series data. In one embodiment, the antibody is a monoclonal or polyclonal antibody or aptamer produced for the rat, rabbit or human form of the biomarker. The detection reagent of the kit includes a second labeled monoclonal or polyclonal antibody or aptamer. Alternatively or additionally, the detection reagent includes a labeled competing antigen.
[0097] In a diagnostic configuration, the test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the method of the present invention. After the specific antigen antibody or aptamer is bound to the reagent, the reagent reacts with an anti-human antibody or aptamer labeled with a reporter gene to bind the reporter gene to the reagent, proportional to the amount of the anti-antigen antibody or aptamer bound to the solid support. The reagent is washed again to remove the unbound labeled antibody or aptamer, and the amount of the reporter gene associated with the reagent is determined. Typically, the reporter gene is an enzyme detected by incubating the solid phase in the presence of a suitable fluorescent, luminescent or colorimetric substrate.
[0098] The solid surface reagents in the above assays are prepared by known techniques for attaching protein or oligonucleotide materials to solid support materials, such as polymer beads, impregnated rods, wells (96-well plates) or filter materials. These attachment methods generally involve non-specific adsorption of the protein oligonucleotide to the support, or covalent attachment of the protein or oligonucleotide to chemically reactive groups on the solid support, such as activated carboxyl, hydroxyl or aldehyde groups, usually through free amino groups. Alternatively, streptavidin-coated plates can be used in conjunction with biotinylated antigens.
[0099] In another embodiment, the kit can include materials for polymerase chain reaction (PCR) amplification to facilitate detection of genetic material prior to determining the amount of a marker for diagnosis of injury, disease or repair, including type, stage, magnitude (severity), subcellular localization, disease state and / or effect of treatment on the patient.
[0100] In some embodiments, the kit may include standard or control information so that the test sample can be compared to the control information standard to determine whether the test amount of the marker detected in the sample is a diagnostic amount consistent with the diagnosis of injury, disease or repair (including type, stage, magnitude (severity), subcellular localization, disease state and / or effect of treatment on the patient).
[0101] In one embodiment, the kit includes: (a) a substrate including an adsorbent thereon, wherein the adsorbent is suitable for binding a marker (e.g., xanthine oxidase and / or xanthine dehydrogenase and / or uric acid), and optionally (b) instructions for detecting the marker by contacting the sample with the adsorbent and detecting the marker retained by the adsorbent. In some embodiments, the kit may include an eluent (as an alternative or in conjunction with the instructions) or instructions for preparing an eluent, wherein the combination of the adsorbent and the eluent allows the marker to be detected using gas phase ion spectrometry. Such a kit can be prepared from the above materials, and the foregoing discussion of these materials (e.g., probe substrates, adsorbents, wash solutions, etc.) is fully applicable to this section and will not be repeated.
[0102] In some embodiments, the kit also includes instructions for suitable operating parameters in the form of a label or separate insert. For example, the kit can have standard instructions that tell the consumer how to clean the probe after the sample contacts the probe. In another example, the kit can have instructions for pre-fractionating the sample to reduce the complexity of the proteins in the sample. In another example, the kit can have instructions for automated fractionation or other processes. Biological samples
[0103] The detection method is capable of detecting and monitoring the level of xanthine oxidase and / or xanthine dehydrogenase and / or uric acid present in a biological sample, improving the diagnostic capability by enabling the clinician to determine the presence, stage and magnitude (severity) of the disease. The biological samples operable herein include body fluids, such as blood, plasma, serum, tears, sweat, urine, feces, cells, tissues, cell or tissue lysates, whole blood or other biological samples recognized in the art, thereby obtaining evidence of increased uric acid concentration or increased XO expression.
[0104] The baseline levels of markers (e.g., XO, xanthine dehydrogenase (or a nucleic acid sequence thereof or a portion thereof) or uric acid) are those levels obtained in target biological samples of desired subject species without known damage, disease or repair. These levels do not need to be expressed in conclusive concentrations, but can be understood from parallel control experiments and expressed in fluorescence units, density units, etc. Typically, the baseline is determined from subjects in which the biomarker is absent or the content is negligible in the biological sample. However, some proteins may be less expressed in injured, ill or repaired patients or before any clinical measurement of damage, disease or repair. It is entirely within the technical scope of the art to determine the baseline levels of protein biomarkers in a particular species. Typically, compared to samples from healthy subjects, increased xanthine oxidase or uric acid levels are higher than the baseline or the ratio of xanthine oxidase to xanthine dehydrogenase is higher or other deviations indicate disease, and can be compared or quantified over time to determine the severity of the disease state or disease or to determine the effectiveness of treatment.
[0105] The markers associated with tissue containing cysts are those obtained in target biological samples of desired subject species without known damage, disease or repair. The level of markers co-localized with xanthine oxidase / dehydrogenase expression or activity may be associated with cystic tissue and regulated directly or indirectly by xanthine oxidase. The markers may be detected in the circulatory system, lymphatic system or excretory system and / or related tissues. Examples of baseline markers include but are not limited to sirtuin or Sirtuin-1, hypoxia-inducible factor-1 (HIF-1), erythropoietin, PCNA, Wnt / B-catenin, IL-5, IL-6, STAT1, STAT2, mTOR, TNFa, MIF, NLRP3 inflammasomes, or cell membranes carried by blood or urine, microvesicles, apoptotic bodies, components of exosomes, or specific parts / fragments of free enzymes or enzymes.
[0106] In order to provide a correlation between damage, disease or repair and measured amounts of xanthine oxidase, biological samples are collected from subjects in whom measurement of these biomarkers is desired to assess damage, disease or repair.
[0107] The detection method can be implemented in the determination or in the test kit for determination. These test kits or determinations are alternatively packaged in a storage box used together with the in vitro diagnostic device of the present invention. Such a device uses these storage boxes, test kits or determinations in the determination module 12, which can be one of a variety of determination types.
[0108] In addition, markers in biological samples, such as xanthine oxidase, xanthine dehydrogenase or uric acid, can be detected by various conventional methods. For example, immunoassays include, but are not limited to, competitive and non-competitive assay systems using, for example, Western blot, radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassay, magnetic immunoassay, radioisotope immunoassay, fluorescence immunoassay, immunoprecipitation assay, precipitin reaction, gel diffusion precipitin reaction, immunodiffusion assay, fluorescence immunoassay, chemiluminescence immunoassay, phosphorescence immunoassay, anodic stripping voltammetry immunoassay and other technologies. The in vitro diagnostic device of the present invention can also include any known device currently available for the reflectance technology of color change on the ion-selective electrode potentiometric assay, microfluidics, fluorescence or chemiluminescence, or optical interpretation protein test strips. These assays are conventional and well known in the art (see, for example, Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference in its entirety into the present invention). An exemplary immunoassay is briefly described below (but is not intended to be limiting). It should be understood that, currently, no prior art provides methods for detecting or measuring any disease disclosed herein, nor does any method exist for detecting any disclosed biomarker using such an in vitro diagnostic device to detect its associated injury.
[0109] Exemplary methods for detecting the presence or absence or relative level above baseline of a marker in a biological sample, alone or in combination, include obtaining a biological sample from a subject (e.g., a human), contacting the biological sample with a compound or reagent (e.g., including an antibody or aptamer) capable of detecting the marker being analyzed, and analyzing the binding of the compound or reagent to the sample after washing. Those samples that have a specifically bound compound or reagent express the marker being analyzed.
[0110] Exemplary in vitro techniques for detecting markers include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, radioassay, Western blot, Southern blot, Northern blot, immunoprecipitation, immunofluorescence, mass spectrometry, RT-PCR, PCR, liquid chromatography, high performance liquid chromatography, enzyme activity assays, cell assays, positron emission tomography, mass spectrometry, combinations thereof, or other techniques known in the art.
[0111] Examples of enzyme (xanthine oxidase) activity assays include, but are not limited to, Cat#8458 from ScienCell Research Laboratories, Cat#MAK078 from Sigma-aldrich, product no. (ab102522 from Abcam; cat no.EXOX-100 from BioAssay Systems. Another example of a xanthine oxidase activity assay is provided in Atlante A, Valenti D, Gagliardi S, Passarella SA sensitive method to assay the xanthine oxidase activity in primary cultures of cerebellar granule cells. Brain Res Brain Res Protoc. 2000 Nov; 6(1-2): 1-5. doi: 10.1016 / s1385-299x(00)00030-1. PMID: 11086257. All of the above are incorporated herein by reference.
[0112] In addition, the in vivo technique of detecting markers comprises introducing the labeling reagent of specific binding markers into biological sample or experimenter.For example, reagent can be used in the radioactive labeling that the existence and position in biological sample or experimenter can be detected by standard imaging technique.It should be understood that the binding reagent determination is easy to form with the reagent that overlaps with space, and detection is carried out by each obviously different detection in xanthine oxidase and / or xanthine dehydrogenase and / or uric acid.The quantization of the binding biomarker based on color intensity of each spatial overlap is exactly the representative of this technology.
[0113] Preferred reagents for detecting markers in biological samples are antibodies, aptamers or nucleic acid probe sequences that can bind to the biomarker being analyzed. More preferably, the antibody, aptamer or nucleic acid probe sequence is coupled to a detectable label. Such antibodies can be polyclonal antibodies or monoclonal antibodies. Complete antibodies, fragments thereof (e.g., Fab or F(ab')2) or engineered variants thereof (e.g., sFv) or aptamers or bi / tri-specific aptamers can also be used. Such antibodies can be any immunoglobulin class, including IgG, IgM, IgE, IgA, IgD and any subclass thereof. Antibodies and aptamers for a variety of biomarkers of the present invention can be obtained from suppliers known to those skilled in the art. Exemplary antibodies operable herein are used to detect biomarkers of the disclosed diseases. In addition, antigens for detecting autoantibodies can also be used to detect late-stage damage to the injuries and diseases.
[0114] In some embodiments of the invention, the antibody or aptamer is labeled. Those of ordinary skill in the art are aware of many labels that can be used herein. Labels include, for example, fluorescent markers, biotin, peroxidase, radionucleotides, or other markers known in the art. Alternatively, another antibody or aptamer or other compound detection species known in the art is used as a form of detection of the biomarker to which the antibody or aptamer binds.
[0115] The antibody and aptamer-based assays operable herein include Western blot immunosorbent assays (e.g., ELISA and RIA) and immunoprecipitation assays. For example, a biological sample or a portion thereof is fixed on a substrate, such as a film made of nitrocellulose or PVDF; or a rigid substrate made of polystyrene or other plastic polymers, such as a microtiter plate, and the substrate is contacted with an antibody or aptamer that specifically binds to a marker under conditions that allow the antibody or aptamer to bind to the biomarker being analyzed. After washing, the presence of an antibody or aptamer on the substrate indicates that the sample contains a marker to be evaluated. If an antibody or aptamer is directly coupled to a detectable marker (e.g., an enzyme, a fluorescent molecule, or a radioisotope), the presence of the marker is optionally detected by checking the detectable marker of the substrate. Alternatively, a second antibody or aptamer that is detectably labeled with a marker-specific antibody or aptamer is added to the substrate. The presence of a detectable marker on the substrate after washing indicates that the sample contains a biomarker.
[0116] Many alternative assays to these basic immunoassays are also operable in the present invention. These include biomarker-specific antibodies or aptamers, and instead of the sample being immobilized on a substrate, contacting the substrate with a biomarker coupled to a detectable marker under conditions that cause the antibody or aptamer to bind to the labeled marker. The substrate is then contacted with the sample under conditions that allow the marker to be analyzed to bind to the antibody or aptamer. A reduction in the amount of detectable marker on the substrate after washing indicates that the sample contains the marker.
[0117] Although antibodies or aptamers are preferred for use in the present invention due to their extensive characterization, any other suitable reagent (e.g., peptide or small organic molecule) that specifically binds to a biomarker may be used in place of an antibody or aptamer in the above-described immunoassay. Methods for preparing aptamers with specific binding specificities are described in detail in U.S. Patent Nos. 5,475,096, 5,670,637, 5,696,249, 5,270,163, 5,707,796, 5,595,877, 5,660,985, 5,567,588, 5,683,867, 5,637,459, and 6,011,020.
[0118] A large number of detectable markers operable in diagnostic assays for biomarker expression are known in the art. The reagents used in the method for detecting biomarkers are coupled to detectable markers (e.g., enzymes, such as horseradish peroxidase). Reagents labeled with horseradish peroxidase can be detected by adding appropriate substrates that produce color changes in the presence of horseradish peroxidase. Several other detectable markers that can be used are known. Common examples of these detectable markers include alkaline phosphatase, horseradish peroxidase, fluorescent compounds, luminescent compounds, colloidal gold, magnetic particles, biotin, radioisotopes, and other enzymes. It should be understood that a primary / secondary antibody or aptamer system can be optionally used to detect one or more biomarkers. A primary antibody or aptamer that specifically recognizes one or more biomarkers is exposed to a biological sample that may contain a biomarker of interest. A secondary antibody or aptamer with an appropriate marker that recognizes the type or isotype of the primary antibody or aptamer is then contacted with the sample to achieve specific detection of one or more biomarkers in the sample.
[0119] The present invention provides a step of comparing the amount of one or more markers with normal levels to determine the disease or condition of the subject. The results of such a test can help doctors determine whether a particular treatment or treatment regimen is effective and provide rapid clinical intervention for injury or disease to enhance the patient's recovery.
[0120] It should be understood that other reagents such as analytical grade water, buffers, membranes, test plates, secondary antibodies or aptamers, salts and other auxiliary reagents can be obtained from suppliers known to those skilled in the art.
[0121] Methods involving conventional biotechnology are described herein. These techniques are generally known in the art and are described in detail in methodological papers, such as Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989 and Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-lnterscience, New York, 1992 (regularly updated). Immunological methods (e.g., preparation of antigen-specific antibodies, immunoprecipitation and immunoblotting) are described in, for example, Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991 and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992. Compositions and preparations
[0122] The present invention provides a composition comprising UALA and an organic base that enhances or affects the dissolution of UALA or uric acid or urate in vivo, and optionally a pharmaceutically acceptable carrier, excipient, solvent or diluent. Preferably, the xanthine oxidase inhibitor and the organic base are selected to ensure the maximum solubility, bioavailability or activity of the xanthine oxidase inhibitor without increasing any side effects. The compositions of the present invention particularly include liquid compositions (e.g., solutions, syrups, colloids or emulsions). In addition, it is envisioned that the composition of the present invention is a micronized, lyophilized or dry spray powder composed of XOI combined with one or more organic molecules or organic bases or basic amino acids, which increases the equilibrium solubility, dissolution or solubility or bioavailability in aqueous solution compared to the acid without oxypurinol in water. Compositions of different combinations of UALA, sirtuin-1 activators, organic bases and / or combined agents are also envisioned herein.
[0123] The present invention contemplates a pharmaceutical composition comprising a unit dose of at least one UALA (e.g., XOI) and an organic base and a pharmaceutically acceptable carrier, excipient, solvent, or diluent. A "unit dose" refers to a single dose, i.e., a single dose, comprising all the ingredients of the composition of the present invention that can be administered to a patient. A "unit dose" can be easily handled and packaged to maintain a physically and chemically stable unit dose comprising an active agent and an organic base and a pharmaceutical carrier, excipient, solvent, or diluent. In an alternative, a dosage kit comprising a xanthine oxidase inhibitor and an organic base and remaining components is provided in separate containers, and the inhibitor and base and remaining components are combined prior to administration. In particular, the dosage kit comprises a xanthine oxidase inhibitor and an organic base in separate containers, and a solution is prepared for use by combining these ingredients with a suitable carrier (e.g., sterile water) prior to administration. The unit dose of UALA or xanthine oxidase inhibitor is an amount sufficient to increase the circulating or tissue concentration of UALA so as to reduce serum uric acid levels by 1%, 3%, 10%, 30%, 50%, 70%, 90%, 95% or more and / or inhibit tissue xanthine oxidase activity by 1%, 3%, 10%, 30%, 50%, 70%, 90%, 95% or more or both. In addition, the dose of UALA will contain 1, 3, 5, 10, 30, 50, 100, 300, 500, 1000 nanograms, micrograms or milligrams of the agent. More specifically, the ratio of UALA to the organic base in the unit dose is 1:0.01, 1:0.1, 1:1, 1:2, 1:3, 1:5 or 1:10 to increase the aqueous solubility and / or oral bioavailability of UALA.
[0124] According to another embodiment, a composition comprising XOI, an organic base and / or choline, and an antioxidant is provided. The antioxidant used in the composition embodiment may include, but is not limited to, α-lipoic acid, n-acetylcysteine, vitamin C.
[0125] Another embodiment relates to a sterile dosage form of a composition comprising UALA and an organic base. In a specific embodiment, the composition comprises a combination of an XOI and a biguanide. In a specific embodiment, a composition comprising an XOI (e.g., oxypurinol, febuxostat, topiroxostat, or allopurinol) and an organic base is provided. The composition may comprise a dosage unit containing 1-2000 mg XOI or 50-2000 mg XOI. In an even more specific embodiment, the dosage unit comprises oxypurinol and an organic base in a molar or weight ratio of about 1:1 to about 1:10.
[0126] The formulation can be provided in a lyophilized form suitable for reconstitution and administration in a subject. A formulation is also provided wherein the XOI, the organic base and the other components of the composition are provided in non-lyophilized or lyophilized form independent of each other. The components can be reconstituted and / or dissolved and combined in a suitable sterile liquid to obtain a pharmaceutical composition suitable for administration to a subject.
[0127] Beneficial effects may also be demonstrated by increased serum levels of the active ingredient after administration compared to the active ingredient alone. They may also be demonstrated by a reduction in serum uric acid levels. They may also be demonstrated by increased uric acid solubility, increased nitric oxide bioavailability, or reduced oxygen free radical production in animals, particularly humans. They may also show reduced xanthine oxidase activity.
[0128] The compositions of the present invention have increased bioavailability (faster absorption and greater absorption) compared to the xanthine oxidase inhibitor alone, as explained by equilibrium solubility, dissolution rate and increased solubility.
[0129] In one aspect, the dissolution rate of the xanthine oxidase inhibitor (i.e., the mass of the substance dissolved in a defined time period) can be increased several times in the compositions of the present invention compared to the pure active substance. The solubility of the xanthine oxidase inhibitor contained in the compositions of the present invention (i.e., the mass of the substance that is significantly dissolved in a certain mass or volume of solvent) can be increased, thereby producing a supersaturated solution. This may result in an increase in final solubility, which is maintained for at least a few hours and then decreases to the saturation level of the solution. In one embodiment, compositions are provided that have an increased absorption rate of 1.5, 2, 3, 4, 5, 10, 15, 20, and 50 times compared to the pure active substance.
[0130] In another embodiment, the present invention provides a composition comprising a xanthine oxidase inhibitor that induces a decrease in intracellular uric acid concentration. In an in vitro uric acid assay or an in vivo assay of serum uric acid or intracellular or tissue uric acid, the decrease in circulating uric acid levels or intracellular uric acid concentration can be expressed as at least about 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70% or a 1, 2, 3, 10, 30 or 100-fold decrease in circulating uric acid levels or intracellular uric acid concentration.
[0131] In a specific embodiment of the present invention, the organic base includes but is not limited to arginine, choline, L-lysine, D-lysine, glucosamine and its N-monosubstituted or N, N-disubstituted derivatives (including but not limited to N-methylglucosamine, N, N-dimethylglucosamine, N-ethylglucosamine, N-methyl, N-ethylglucosamine, N, N-diethylglucosamide, N-β-hydroxyethylglucosamine, N-methyl, N-β-hydroxyethylglucosamine and N, N-di-β-hydroxyethylglucosamine), phenethylbenzylamine, benzathine, betaine, diarno, diethylamine, 2-(diethylamino)-ethanol, sea salt. In some embodiments, the organic base is hydrabamine, 4-(2-hydroxyethyl)-morpholine, 1-(2-hydroxyethyl)-pyrrolidine, tromethamine, diethanolamine (2,2"-iminobis(ethanol)), ethanolamine (2-aminoethanol), 1H-imidazole, piperazine, triethanolamine (2,2',2"-nitrilotri(ethanol)), N-methylmorpholine, N-ethylmorpholine, pyridine, dialkylaniline, diisopropylcyclohexylamine, tertiary amines (such as triethylamine, trimethylamine), diisopropylethylamine, dicyclohexylamine, N-methyl-D-glutamine, 4-pyrrolidinylpyridine, dimethylaminopyridine (DMAP), piperidine, isopropylamine or caffeine. In other embodiments, the organic base is a biguanide or a biguanide, such as metformin. In other embodiments, the organic base is gliflozin.
[0132] In another embodiment, the organic base is a basic amino acid, particularly lysine and arginine, and the xanthine oxidase inhibitor is allopurinol or oxypurinol. In one embodiment, a liquid composition comprising allopurinol or oxypurinol and L-arginine is provided.
[0133] In another embodiment, the xanthine oxidase inhibitor and basic amino acid composition can be administered to an animal or human subject as a powder, the solubility of the composition increasing upon contact with water or other aqueous solutions or food materials in the gastrointestinal tract sufficient to produce a liquid dosage form.
[0134] In another embodiment, the present invention provides a composition, particularly a liquid composition, comprising a xanthine oxidase inhibitor and choline. Choline is a physiological compound that has been used therapeutically without the disadvantages of, for example, systemic or local toxicity.
[0135] The ratio of XOI to organic base can be selected to increase the solubility of XOI, increase the activity of XOI or provide a beneficial effect. The ratio of organic base to xanthine oxidase inhibitor can be about 0.01 to 20.0 molar equivalents of organic base to 1.0 molar equivalent of XOI. In one embodiment, the ratio of organic base to XOI is 1.0:0.5 molar, particularly 1.0:1.0 molar, more particularly 1.0:3.0 molar. In a specific embodiment, the composition comprises oxypurinol as XOI and metformin as organic base, wherein the ratio of oxypurinol to metformin is 1:01 to 1:10 molar.
[0136] The composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient, solvent or diluent. XOI and the organic base may be mixed into a selected pharmaceutically acceptable carrier, excipient, solvent or diluent, and other active ingredients including therapeutic agents may be optionally added.
[0137] The composition of the present invention generally comprises a suitable pharmaceutical carrier, excipient, solvent or diluent selected according to the expected form of administration and in accordance with conventional pharmaceutical practice. Suitable pharmaceutical carriers, excipients, solvents or diluents are described in the standard textbook Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, Pa., USA 1985). For example, for oral administration in liquid form, the drug component (i.e., XOI and organic base) can be combined with any oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Suitable adhesives (e.g., gelatin, starch, corn sweeteners, natural sugars including glucose; natural and synthetic gums and waxes), lubricants (e.g., sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride), disintegrants (e.g., starch, methylcellulose, agar, bentonite and xanthan gum), flavoring agents, targeting agents, coloring agents and other agents known to those skilled in the art can also be combined in the composition or its components.
[0138] In one embodiment, the composition of the invention is formulated so that it remains active at physiological pH. The composition may be formulated in the pH range of 4 to 10, particularly 5 to 9.
[0139] In one aspect, the invention relates to an aqueous composition comprising an XOI of the invention and a solvent system that affects the solubility of the inhibitor. The solvent system affects the solubility of the inhibitor to provide an aqueous solution with beneficial properties for incorporation into an oral liquid formulation. The solvent system comprises an organic base, particularly arginine or lysine, more particularly arginine.
[0140] In one aspect, a liquid composition can be prepared using a XOI, particularly allopurinol or oxypurinol, and arginine, choline, glucosamine (n-methylglucosamine), or a glucosamine salt.
[0141] In one aspect, the invention provides a sterile, pyrogen-free, ready-to-use solution of XOI, in particular allopurinol or oxypurinol, consisting essentially of XOI and an organic base dissolved in a physiologically acceptable solvent. In one embodiment, the solution has not been reconstituted from a lyophilisate.
[0142] The present invention also provides a composition for oral administration comprising XOI and an organic base dissolved in a physiologically acceptable solvent.
[0143] In a specific liquid composition of the present invention comprising oxypurinol and arginine, the concentration of oxypurinol is about 0.1-100 mg / ml, 0.5-50 mg / ml, 1-25 mg / ml and 1-10 mg / ml, more preferably 10 mg / ml. The solution can be administered in a total volume of about 5 to 100 ml, preferably 30 ml, twice a day to achieve a desired dose of about 200 to 1000 mg / day, preferably 600 mg / day. Alternatively, if a once-a-day administration regimen is desired, the concentration of oxypurinol in the preparation can be about 6.0 to 60 mg / ml, preferably 20 mg / ml, administered once a day in a solution of about 10 to 100 ml, preferably 30 ml.
[0144] The preferred liquid formulation of the present invention comprises: (1) allopurinol, oxypurinol, febuxostat or their tautomers, in a concentration range of about 0.1 to about 100 mg / ml (w / v), more preferably about 0.5 to about 50 mg / ml (w / v), even more preferably about 1 to about 25 mg / ml (w / v), still more preferably about 1 to 10 mg / ml (w / v), and most preferably about 10 mg / ml; (2) a basic amino acid having an appropriate concentration range so that the molar ratio of the basic amino acid to XOI or metformin is appropriate; and (3) a pharmaceutically acceptable diluent, preferably water, to bring the composition to a specified volume.
[0145] The present invention contemplates the lyophilized formulations described herein. The lyophilized compositions of the present invention may provide products with increased stability, solubility or bioavailability. The lyophilized formulation of XOI comprises: XOI, an organic base and a pharmaceutically acceptable carrier, excipient or diluent. The storage conditions of the lyophilized formulation are generally about 2°C to about 25°C. XOI containing an organic base (e.g., arginine) can be lyophilized in an initial solution at a concentration of about 0.02 mg / ml to about 10 mg / ml of the compound. The lyophilized solution preferably comprises an organic base and a lyophilization buffer in addition to XOI. The preferred pH range of the lyophilization buffer is about 5.5 to about 12.0. The lyophilization buffer may comprise sodium citrate, EDTA and / or sucrose. The lyophilized xanthine oxidase preparation can be reconstituted in sterile water to maintain isotonic conditions of about 290 mOsm. XOI and the organic base can be reconstituted in sterile water optionally containing a stabilizing amount of an antioxidant. Example
[0146] Figure 1: Purine metabolism and purine-based xanthine oxidase inhibitor metabolism Schematic diagram of the enzyme hypoxanthine. Xanthine oxidase and xanthine dehydrogenase are involved in the enzymatic conversion of hypoxanthine to xanthine and then to uric acid. Uricase is active in many other life forms besides humans, apes, and Dalmatian dogs, and further converts uric acid to allantoin. Aldehyde oxidase and xanthine oxidase rapidly convert allopurinol to oxypurinol.
[0147] Figure 2: Modulators of Xanthine Oxidase / Xanthine Dehydrogenase Schematic diagram of . Ischemia, oxidative stress, and inflammation are associated with increased xanthine oxidase activity and decreased sirtuin-1 activity. In disease, xanthine oxidase activity and activation lead to increased uric acid and oxygen free radical production. Inhibition of xanthine oxidase activity both intracellularly and extracellularly can reduce tissue damage. SGLT2 inhibitors activate sirtuin-1 activity, which in turn reduces xanthine oxidase activity. SGLT2 inhibition can indirectly protect cystic tissue that overexpresses xanthine oxidase by inhibiting xanthine oxidase activity, reducing uric acid and oxygen free radicals in tissues. Both xanthine oxidase inhibition and SGLT2 inhibition can exert protective effects on cystic tissue. SGLT2 inhibitors increase Sirtuin1 activity, which inactivates xanthine oxidase activity, thereby acting as uric acid lowering agents. SGLT2 inhibitors have also been reported to reduce uric acid by reducing uric acid reabsorption in the kidney and intestine.
[0148] Figure 3: Shows that animal models of polycystic kidney disease display high serum allantoin concentrations. Increased allantoin has been previously reported in the Han / SPRD rat model of polycystic kidney disease (Edelstein et al.). Increased allantoin occurs early in the polycystic kidney disease mouse model and persists from as early as 3 months to 9 months in RC / RC mice. Since allantoin is a product of uric acid breakdown by uricase, this finding supports the view that long-term high exposure to uric acid persists in polycystic kidney disease and may lead to health consequences and progression of decreased renal structure and function.
[0149] Figure 4: Data are provided showing increased renal tissue expression of XO in rodent models of polycystic kidney disease. In advanced polycystic kidney disease, xanthine oxidase was identified and quantified in renal tissue, wild-type (WT) and advanced PKD rats CY / + and RC / RC mice. Statistically significant (*; **) increases in xanthine oxidase protein concentrations were observed using Western blots. Figure 4A provides a Western blot showing increased expression of xanthine oxidase. Figure 4B provides data from kidneys of Han / SPDR (CY / +) or wild-type rats, a rat model of polycystic kidney disease. Light microscopy images of renal tissue sections, stained to show the presence of xanthine oxidase, and read in relative density units (RD). Han / SPDR showed an increased proportion of cytoplasmic staining compared to wild type (p<0.05). Figure 4C provides evidence of similar observations in a mouse model of polycystic kidney disease (Pkd1 RC / RC mice) (P<0.05).
[0150] Figure 5: Increased XO activity in rodent models of polycystic kidney disease renal tissue compared to wild type. In advanced polycystic kidney disease, xanthine oxidase activity was quantified in renal tissue, wild type (WT) and advanced PKD rats CY / +. A statistically significant increase in xanthine oxidase activity was observed in Han / SPDR rats.
[0151] Figure 6: Data presented show that in a rat model of polycystic kidney disease (PCK) and a mouse model of polycystic kidney disease (Pkd1RC / RC), uricase inhibition by oxonic acid (OXO) and the corresponding increase in uric acid are associated with an increase in the total kidney to body weight ratio (2K / BWT). The rodent model of polycystic kidney disease was treated with the uricase inhibitor, oxonic acid (OXO), to reduce the metabolism of uric acid to allantoin, thereby chronically increasing circulating serum uric acid concentrations. After 8 weeks of treatment with oxonic acid, total kidney volume increased significantly compared to untreated animals. After 70 days of exposure to oxonic acid, both models showed similar results, with increased serum uric acid leading to increases in 2K / BWT, increased cyst size, and increased serum creatinine (P<0.05; P<0.05; P<0.07 & P<0.05 for creatinine in rats and mice). Increased serum uric acid is associated with structural and functional changes in renal function. Increased creatinine is associated with decreased filtration capacity in nephropathy. This result suggests that uric acid regulates cystogenesis and cyst growth rate, thereby regulating kidney structure and disease progression. Figure 6A shows data from the PCK rat model, and Figure 6B shows data from the mouse RC / RC model.
[0152] Figure 7: Presents data demonstrating that in a rodent model of polycystic kidney disease, uricase inhibition by oxonic acid and corresponding elevations in uric acid indicate decreased renal function as shown by increased creatinine in serum.
[0153] Figure 8 : In a rodent model of polycystic kidney disease—the mouse RC / RC model—xanthine oxidase inhibition slowed the progression of renal disease, as measured by mean total kidney volume ( Figure 8 A) and the median size of cysts in the kidney ( Figure 8 This suggests that inhibition of uric acid production by xanthine oxidase may reduce kidney size in polycystic kidney disease compared with placebo (veh).
[0154] Fig. 9 : showed that in a rodent model of polycystic kidney disease, mice RC / RC, oxonic acid (OXO) exposure increased kidney size. When OXO and xanthine oxidase inhibition (OXY+L) were co-administered, OXY+L at moderate doses (8 mg / kg / day) or higher oral doses (24 mg / kg / day) attenuated the effects of oxonic acid and normalized / reduced UA-induced renal dilatation. These data suggest that the deleterious effects of hyperuricemia can be mitigated by lowering uric acid levels with UALA.
Claims
1. A method for detecting and treating progression of renal disease in a subject, the method comprising obtaining a sample from a subject; and detecting the expression or activity level of xanthine oxidase in the sample, and determining that the subject is a subject in need thereof if the expression or activity level of xanthine oxidase is at or above a predetermined level or is increased relative to a control; and A therapeutically effective amount of a xanthine oxidase inhibitor is administered to a subject in need thereof.
2. The method of claim 1, wherein the renal disease progression is polycystic kidney disease progression.
3. The method of claim 2, wherein the polycystic kidney disease progression is autosomal dominant or autosomal recessive polycystic kidney disease.
4. The method according to any one of claims 1 to 3, wherein the sample comprises a body fluid, wherein the body fluid is optionally blood, plasma, serum, tears, sweat, urine, feces or tissue.
5. The method according to any one of claims 1 to 4, further comprising detecting the uric acid concentration in the sample from the subject or another sample, wherein the uric acid concentration is at or above a predetermined level or is elevated relative to a control further indicating kidney disease progression.
6. The method according to any one of claims 1 to 5, wherein the sample is blood, urine or both, and the detection comprises detecting an antigen associated with XO or XDH or both or an amino acid chain fragment of XO or XDH.
7. The method of any one of claims 1 to 6, wherein the xanthine oxidase inhibitor comprises oxypurinol.
8. The method of claim 7, wherein the composition further comprises an organic base, wherein the organic base is optionally one or more of L-arginine, D-arginine, choline, L-lysine, D-lysine, caffeine, biguanide, biguanide or gliflozin.
9. The method according to claim 7, further comprising co-administering a therapeutically effective amount of an organic base.
10. A method comprising detecting a change in xanthine oxidase (XO) concentration or activity, xanthine dehydrogenase (XDH) concentration or activity, or the ratio of XO / XDH concentration or activity, the method comprising: obtaining a sample from a subject exhibiting one or more symptoms of polycystic kidney disease, wherein the sample comprises a blood sample or a urine sample or an extracellular vesicle sample from a blood sample or a urine sample; and detecting the concentration or activity of XO and the concentration or activity of XDH in the sample; and If the sample comprises an XO concentration or activity, an XDH concentration or activity and / or a ratio of XO / XDH concentration or activity that deviates from that of a healthy subject, UALA and optionally in combination with an organic base is administered.
11. The method of claim 10, wherein the deviation from healthy subjects is XO concentration is greater than 1 mg / L; XO enzyme activity greater than 105 (U / L); and / or XO / XDH differs from that of healthy subjects by at least 0.1-10%.
12. A method of reducing abnormal purine metabolism associated with kidney disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of one or more uric acid lowering agents, wherein the method treats symptoms of cystic disease, and wherein the one or more uric acid lowering agents are optionally selected from the group consisting of xanthine oxidase inhibitors and sirtuin-1 activators.
13. The method of claim 12, wherein the subject in need thereof has one or more cysts in the kidney or liver.
14. The method of claim 12, wherein administering comprises administering oxypurinol and gliflozin in combination.
15. A method of reducing a marker of kidney disease progression in a subject, the method comprising obtaining a sample from a subject; and Detection of markers of kidney disease, including tissue oxygen free radicals, uric acid, cytokines, inflammatory cells, fibrosis, mitochondrial proliferation, or Sirtuin-1 in the sample, and If the marker level is above baseline, a therapeutically effective amount of UALA, optionally in combination with an organic base, is administered to a subject in need thereof.
16. The method of claim 15, wherein the renal disease progression is polycystic kidney disease progression.
17. The method according to claim 15 or 16, wherein UALA is an interfering molecule targeting the expression of xanthine oxidase or xanthine dehydrogenase, or is an eRNA that increases the expression of sirtuin-1.
18. The method of claim 17, wherein administering comprises administering a xanthine oxidase inhibitor in combination with an interfering molecule targeting the expression of xanthine oxidase or xanthine dehydrogenase.
19. A method comprising detecting the presence of a marker or a ratio of a marker in a biological sample from a subject; if the marker is elevated relative to a baseline or a control, or if the ratio of the marker is disproportionate to the baseline or the control, administering to the subject a therapeutically effective amount of at least one urate-lowering agent.
20. The method of claim 19, wherein the marker is one or more of xanthine oxidase, xanthine dehydrogenase, sirtuin or sirtuin-1, hypoxia-inducible factor-1 (HIF-1), erythropoietin, PCNA, Wnt / B-catenin, IL-5, IL-6, STAT1, STAT2, mTOR, TNFa, MIF, NLRP3 inflammasome, or components of cell membranes, microvesicles, apoptotic bodies, exosomes carried by blood or urine, or free enzymes or specific parts / fragments of enzymes.
21. The method of claim 20, wherein the ratio comprises a xanthine oxidase / xanthine dehydrogenase ratio.
22. The method of claim 20, wherein the uric acid lowering agent is a xanthine oxidase inhibitor, or an interfering molecule targeting the expression of XO or XDH in cells of the subject.
23. The method of any one of claims 20 to 22, further comprising administering a combination agent.
24. The method of claim 23, wherein the co-agent is a vasopressin receptor antagonist.
25. A method comprising administering a therapeutically effective amount of a uric acid-lowering agent to a subject whose xanthine oxidase activity or concentration in a urine sample is elevated relative to that of healthy subjects or whose XO / XDH concentration or activity ratio deviates from that of healthy subjects.
26. The method of claim 25, further comprising administering a combination agent.
27. A method for monitoring the effectiveness of a treatment for polycystic kidney disease, comprising: administering an amount of a uric acid-lowering agent to a subject having an increased xanthine oxidase activity or concentration in the subject's urine relative to a baseline, or an increased xanthine oxidase / xanthine dehydrogenase activity or concentration ratio relative to a baseline; and The xanthine oxidase concentration or activity or the ratio of xanthine oxidase / xanthine dehydrogenase concentration or activity in the subject's urine is detected, wherein a decrease in xanthine oxidase activity or concentration or a shift in the ratio of xanthine oxidase / xanthine dehydrogenase concentration or activity toward baseline indicates treatment effectiveness.
28. A composition comprising an amount of oxypurinol and an amount of metformin and / or an SGLT2 inhibitor.
29. The composition of claim 28, wherein the SGLT2 inhibitor is gliflozin.
30. The composition of claim 28, comprising oxypurinol, metformin and gliflozin.
31. A method for treating polycystic kidney disease comprising administering a therapeutically effective amount of the composition of any one of claims 28 to 30.
32. A method for treating polycystic kidney disease comprising administering a therapeutically effective amount of a xanthine oxide inhibitor and metformin in combination.
33. A composition comprising a therapeutically effective amount of a uric acid lowering agent and a therapeutically effective amount of tolvaptan and / or rivaptan.
34. The composition of claim 33, wherein the uric acid lowering agent is a xanthine oxidase inhibitor.
35. The method of claim 34, wherein the xanthine oxidase inhibitor is oxypurinol.
36. A method for treating polycystic kidney disease comprising administering a therapeutically effective amount of the composition of any one of claims 33 to 35.
37. A method for treating polycystic kidney disease, comprising administering a therapeutically effective amount of a xanthine oxide inhibitor in combination with tolvaptan and / or rivaptan.
38. A method of treating cystic disease in a subject in need thereof, the method comprising co-administering a therapeutically effective amount of a urate-lowering agent and a gliflozin, wherein the gliflozin is co-administered in an amount that increases the aqueous solubility and bioavailability of the urate-lowering agent.
39. A method for treating cystic disease comprising administering a therapeutically effective amount of a xanthine oxidase inhibitor and a Sirtuin-1 activator in combination.
40. The method of claim 39, wherein the sirtuin-1 activator is a SGLT2 inhibitor.
41. The method of claim 39 or 40, wherein the method ameliorates the development or growth of a cyst.
42. The method of any one of claims 39 to 41, wherein the cystic disease is polycystic kidney disease.
43. A method of treating cystic disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of at least one xanthine oxidase inhibitor in combination with an agent that directly or indirectly reduces the expression of xanthine oxidase.
44. The method of claim 43, wherein the agent that directly reduces the expression of xanthine oxidase comprises an interfering molecule that targets the expression of xanthine oxidase.
45. The method of claim 43, wherein the agent that indirectly reduces xanthine oxidase expression comprises a sirtuin-1 activator.
46. The method of claim 45, wherein the sirtuin-1 activator comprises gliflozin or an eRNA that induces sirtuin-1 expression, or a combination thereof.
47. A composition comprising a therapeutically effective amount of a xanthine oxidase inhibitor and an agent that directly or indirectly reduces the expression of xanthine oxidase.
48. The composition of claim 47, wherein the agent that directly reduces the expression of xanthine oxidase comprises an interfering molecule that targets the expression of xanthine oxidase.
49. The composition of claim 47, wherein the agent that indirectly reduces xanthine oxidase expression comprises a sirtuin-1 activator.
50. The composition of claim 49, wherein the sirtuin-1 activator comprises gliflozin or an eRNA that induces sirtuin-1 expression, or a combination thereof.
